This year's most-read news on MHE features "Paxlovid Rebound: Rare But Real," "John Fetterman’s Atrial Fibrillation and Stroke: ‘I Almost Died’," "Pandemic Mortality Rate Much Lower in Canada Than in the US. Why?," and more.
Advertisement
Paxlovid Rebound: Rare But Real Mayo Clinic researchers reported in the journal Clinical Infectious Diseases that less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19. Read more
Diabetes Medications Find New Life as Weight-Loss Drugs Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite. But their cost-effectiveness is in question, and many payers are saying no to coverage — for now. Read more
John Fetterman’s Atrial Fibrillation and Stroke: ‘I Almost Died’ Lack of an adherence may have been a factor. The Democratic Senate candidate stopped taking the medications he was prescribed after being diagnosed with atrial fibrillation in 2017. Read more
Childhood Insomnia Symptoms Often Persist into Adulthood, Study Finds Children with poor sleep had a 2.6-fold higher risk of developing adult insomnia, according to longitudinal research conducted by Penn State researchers. Read more
Pandemic Mortality Rate Much Lower in Canada Than in the US. Why? Some researchers have pointed to the benefits of a single-payer system such as the one in Canada. But the author of the PNAS commentary, David Fisman, say it may be trace back to the more communitarian outlook of Canadians. Read more
Will Carroll, Pharm.D., of Sutter Health says pharmacy is often handed strategy to execute instead of shaping it, and must show value in C-suite terms.
Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in cardiovascular prevention.
Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, is now the biggest barrier.
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.